Cost-effectiveness of population-based genetic hemochromatosis screening

Show simple item record

dc.identifier.uri http://dx.doi.org/10.15488/3622
dc.identifier.uri https://www.repo.uni-hannover.de/handle/123456789/3654
dc.contributor.author Schöffski, Oliver
dc.contributor.author Schmidtke, Jörg
dc.contributor.author Stuhrmann, Manfred
dc.date.accessioned 2018-08-23T12:59:40Z
dc.date.available 2018-08-23T12:59:40Z
dc.date.issued 2000
dc.identifier.citation Schöffski, O.; Schmidtke, J.; Stuhrmann, M.: Cost-effectiveness of population-based genetic hemochromatosis screening. In: Community Genetics 3 (2000), Nr. 1, S. 2-11. DOI: https://doi.org/10.1159/000016220
dc.description.abstract Objective: Evaluation of the costs of a population-based genetic hemochromatosis (HH) screening. Methods: We performed a decision tree analysis and subsequently quantified the screening and treatment costs and the effect on life expectancies. Assumptions were based on literature data and expert opinions. Results: Under the very conservative assumptions of a 10% penetrance, a carrier frequency of 10%, a mean age of onset of complications of 54 years, and a 90% compliance with treatment (phlebotomy), we calculated the cost to be 7.26 EUR per tested person versus 1.62 EUR per nontested person (1 EUR ≃ 1 USD). The life expectancies for a 25-year-old male are 48.99843 years (if not tested) versus 48.99970 years (if tested). Although increased life expectancy for the entire population as a result of screening is negligible, for the 1 in 4,000 men who could benefit from it, an average of 2,000 extra days will be gained. By dividing the difference of cost by the difference of life expectancy, we calculated the cost for one life year gained to be 4,441 EUR. Under less stringent conditions (higher penetrance, higher carrier frequency) the costs decrease substantially. Conclusion: Costs of population-based genetic HH screening are very acceptable compared to the costs of other health care measures. We conclude that genetic HH screening is feasible under economic aspects of health care. Copyright (C) 2000 S. Karger AG, Basel. eng
dc.language.iso eng
dc.publisher Basel: S. Karger
dc.relation.ispartofseries Community Genetics 3 (2000), Nr. 1
dc.rights Es gilt deutsches Urheberrecht. Das Dokument darf zum eigenen Gebrauch kostenfrei genutzt, aber nicht im Internet bereitgestellt oder an Außenstehende weitergegeben werden. Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
dc.subject Costs eng
dc.subject Decision tree eng
dc.subject Economic evaluation eng
dc.subject Hemochromatosis eng
dc.subject Screening eng
dc.subject article eng
dc.subject cost effectiveness analysis eng
dc.subject decision making eng
dc.subject economic aspect eng
dc.subject genetic screening eng
dc.subject hemochromatosis eng
dc.subject human eng
dc.subject life expectancy eng
dc.subject priority journal eng
dc.subject public health eng
dc.subject screening test eng
dc.subject.ddc 330 | Wirtschaft ger
dc.subject.ddc 610 | Medizin, Gesundheit ger
dc.title Cost-effectiveness of population-based genetic hemochromatosis screening
dc.type article
dc.type Text
dc.relation.issn 14222795
dc.relation.doi https://doi.org/10.1159/000016220
dc.bibliographicCitation.issue 1
dc.bibliographicCitation.volume 3
dc.bibliographicCitation.firstPage 2
dc.bibliographicCitation.lastPage 11
dc.description.version publishedVersion
tib.accessRights frei zug�nglich


Files in this item

This item appears in the following Collection(s):

Show simple item record

 

Search the repository


Browse

My Account

Usage Statistics